Diabetic Nephropathy Market
Diabetic Nephropathy Market Forecasts to 2030 - Global Analysis By Type (Type-1 Diabetes, Type-2 Diabetes and Other Types), By Diagnosis Type (Blood Test, Urine Test, Imaging Test, Renal Function Testing, Kidney Biopsy and Other Diagnosis Types), By Treatment, Route of Administration, Distribution Channel, End Users and By Geography
|
Years Covered |
2021-2030 |
|
Estimated Year Value (2023) |
US $2.7 BN |
|
Projected Year Value (2030) |
US $4.1 BN |
|
CAGR (2023 - 2030) |
5.8% |
|
Regions Covered |
North America, Europe, Asia Pacific, South America, and Middle East & Africa |
|
Countries Covered |
US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa |
|
Largest Market |
North America |
|
Highest Growing Market |
Asia Pacific |
According to Stratistics MRC, the Global Diabetic Nephropathy Market is accounted for $2.7 billion in 2023 and is expected to reach $4.1 billion by 2030 growing at a CAGR of 5.8% during the forecast period. Diabetic Nephropathy is a kidney condition resulting from diabetes, characterized by kidney damage due to prolonged high blood sugar levels. Its early detection through regular screening allows for timely intervention, including lifestyle modifications and medications, preventing or slowing progression and reducing the risk of complications associated with advanced kidney disease.
According to the International Diabetes Federation (IDF), 40% of diabetics may experience kidney failure in its ultimate stages. Furthermore, about 80% of end-stage renal failure is caused by diabetes and hypertension, either together or individually.
Market Dynamics:
Driver:
Increased awareness and proactive screening programs
Awareness campaigns educate individuals about the risks of kidney complications associated with diabetes, more people are encouraged to undergo regular screenings for early detection. Early identification enables prompt intervention and management, potentially slowing the progression of diabetic nephropathy and reducing associated complications. Proactive screening not only contributes to better patient outcomes but also enhances the overall effectiveness of healthcare systems in managing diabetic nephropathy. This driver underscores the importance of preventive healthcare measures, empowering individuals to take proactive steps in addressing diabetic nephropathy and promoting better long-term health outcomes.
Restraint:
High treatment costs
The complex nature of managing diabetic nephropathy, which may involve medications, lifestyle modifications, and, in severe cases, renal replacement therapies, contributes to elevated healthcare expenses. The financial burden associated with consistent medical appointments, medications, and potential dialysis or kidney transplantation can limit access to optimal care, especially for individuals with limited financial resources. This economic barrier may result in delayed or inadequate treatment, adversely impacting patient outcomes.
Opportunity:
Government initiatives for diabetes management
As governments globally prioritize public health, initiatives aimed at preventing and managing diabetes directly benefit the market. Policies supporting awareness campaigns, diabetes education, and accessible screening programs contribute to early detection and intervention in diabetic nephropathy cases. Government-backed healthcare programs and subsidies for medications can enhance patient access to treatment, fostering a more conducive environment for market growth. Collaboration between healthcare authorities and the pharmaceutical industry to align with these initiatives not only addresses the societal burden of diabetes but also creates a supportive framework for the expansion of diabetic nephropathy management solutions.
Threat:
Side effects associated with certain medications
Pharmaceutical interventions play a crucial role in managing diabetic nephropathy, the potential adverse effects of medications may lead to patient apprehension, non-compliance, or discontinuation of treatment. Side effects such as gastrointestinal issues, hypoglycemia, and renal complications can compromise the overall well-being of patients. This threat underscores the importance of developing and prescribing medications with favorable safety profiles. Pharmaceutical companies and healthcare providers must prioritize research and innovation to minimize side effects, ensuring that the benefits of treatment outweigh potential risks.
Covid-19 Impact:
The Covid-19 pandemic has had a multifaceted impact on the Diabetic Nephropathy Market. Disruptions in healthcare services, patient hesitancy to seek non-urgent medical care, and diversion of resources to pandemic management have collectively affected the diagnosis and management of diabetic nephropathy. However, the pandemic has also emphasized the importance of proactive management and highlighted opportunities for telemedicine and digital health solutions to enhance remote monitoring and patient care in the diabetic nephropathy landscape.
The urine test segment is expected to be the largest during the forecast period
The urine test segment is expected to have a lucrative growth. These tests, such as albuminuria and proteinuria assessments, help in early detection of kidney damage caused by diabetes. Monitoring the presence of abnormal levels of proteins in the urine aids healthcare professionals in assessing the progression of nephropathy. Regular urine testing allows for timely intervention and personalized treatment plans, contributing to better management of diabetic nephropathy and improved patient outcomes. It serves as a non-invasive and cost-effective diagnostic tool, supporting effective healthcare strategies in combating this complication of diabetes.
The hospitals segment is expected to have the highest CAGR during the forecast period
The hospitals segment is anticipated to witness the fastest CAGR growth during the forecast period. These healthcare institutions provide essential services, including diagnostic screenings, consultations with nephrologists, and access to a range of therapeutic interventions. Hospitals also facilitate more advanced treatments like dialysis and kidney transplantation for severe cases. Additionally, they serve as hubs for patient education, contributing to increased awareness and proactive management of diabetic nephropathy. The collaborative efforts of hospitals, healthcare professionals, and patients are critical in addressing the challenges posed by diabetic nephropathy and improving patient outcomes.
Region with largest share:
During the forecast period, it is expected that the North American market will continue to hold a majority of the market share. The region's advanced medical research capabilities contribute to early detection, innovative therapies, and a robust pharmaceutical market. Government initiatives, healthcare policies, and a heightened awareness of diabetes further support the market's growth. With a growing aging population and a focus on preventive healthcare, North America continues to be a key player in shaping advancements and solutions for the effective management of diabetic nephropathy.
Region with highest CAGR:
Asia Pacific is projected to have the highest CAGR over the forecast period. The region's rising prevalence of diabetes, particularly in countries like China and India, amplifies the demand for diabetic nephropathy management. Government initiatives, improving healthcare infrastructure, and growing investments in research and development contribute to the market's expansion. As the region grapples with the diabetes epidemic, the Diabetic Nephropathy Market in Asia Pacific is positioned for substantial growth, presenting opportunities for healthcare providers and pharmaceutical companies to address the evolving healthcare needs of the population.
Key players in the market
Some of the key players in Diabetic Nephropathy market include F. Hoffmann-La Roche Ltd, Fresenius Kabi AG, GlaxoSmithKline Plc., Hebei Changshan Biochemical Pharmaceutical Co. Ltd., Hikma Pharmaceuticals PLC, Mylan N.V., Novartis AG, Pfizer Inc, Teva Pharmaceutical Industries Ltd., Bayer AG and Bristol Myers Squibb Company.
Key Developments:
In March 2023, Novartis announced that it had submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for renoprotective effects of sevelamer carbonate, a phosphate binder, for the treatment of diabetic nephropathy.
In January 2023, Boehringer Ingelheim and Eli Lilly and Company announced that US Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for Jardiance (empagliflozin) investigating a potential new indication to lower blood sugar along with diet and exercise in children 10 years and older with type 2 diabetes. These tablets have been investigated as a possible therapy to reduce the chance of cardiovascular death and kidney disease progression in adults with chronic kidney disease.
In December 2022, Bayer launched Finerenone under the brand name Kerendia in India. Finerenone is a first-in-class non-steroidal, selective mineralocorticoid receptor antagonist indicated for patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).
Types Covered:
• Type-1 Diabetes
• Type-2 Diabetes
• Other Types
Diagnosis Types Covered:
• Blood Test
• Urine Test
• Imaging Test
• Renal Function Testing
• Kidney Biopsy
• Other Diagnosis Types
Treatments Covered:
• Medication
• Kidney Dialysis
• Transplant
Route of Administrations Covered:
• Oral
• Parental
• Other Route of Administrations
Distribution Channels Covered:
• Online Pharmacy
• Retail Pharmacy
End Users Covered:
• Hospitals
• Homecare
• Speciality Centres
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Diabetic Nephropathy Market, By Type
5.1 Introduction
5.2 Type-1 Diabetes
5.3 Type-2 Diabetes
5.4 Other Types
6 Global Diabetic Nephropathy Market, By Diagnosis Type
6.1 Introduction
6.2 Blood Test
6.3 Urine Test
6.4 Imaging Test
6.5 Renal Function Testing
6.6 Kidney Biopsy
6.7 Other Diagnosis Types
7 Global Diabetic Nephropathy Market, By Treatment
7.1 Introduction
7.2 Medication
7.2.1 Diuretics
7.2.2 Antioxidant Inflammation Modulator
7.2.3 Angiotensin Receptor Blockers
7.2.4 Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
7.2.5 Renin Inhibitors
7.2.6 Calcium Channel Blockers
7.2.7 Other Medications
7.3 Kidney Dialysis
7.4 Transplant
8 Global Diabetic Nephropathy Market, By Route of Administration
8.1 Introduction
8.2 Oral
8.3 Parental
8.4 Other Route of Administrations
9 Global Diabetic Nephropathy Market, By Distribution Channel
9.1 Introduction
9.2 Online Pharmacy
9.3 Retail Pharmacy
10 Global Diabetic Nephropathy Market, By End User
10.1 Introduction
10.2 Hospitals
10.3 Homecare
10.4 Specialty Centers
10.5 Other End Users
11 Global Diabetic Nephropathy Market, By Geography
11.1 Introduction
11.2 North America
11.2.1 US
11.2.2 Canada
11.2.3 Mexico
11.3 Europe
11.3.1 Germany
11.3.2 UK
11.3.3 Italy
11.3.4 France
11.3.5 Spain
11.3.6 Rest of Europe
11.4 Asia Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Australia
11.4.5 New Zealand
11.4.6 South Korea
11.4.7 Rest of Asia Pacific
11.5 South America
11.5.1 Argentina
11.5.2 Brazil
11.5.3 Chile
11.5.4 Rest of South America
11.6 Middle East & Africa
11.6.1 Saudi Arabia
11.6.2 UAE
11.6.3 Qatar
11.6.4 South Africa
11.6.5 Rest of Middle East & Africa
12 Key Developments
12.1 Agreements, Partnerships, Collaborations and Joint Ventures
12.2 Acquisitions & Mergers
12.3 New Product Launch
12.4 Expansions
12.5 Other Key Strategies
13 Company Profiling
13.1 F. Hoffmann-La Roche Ltd
13.2 Fresenius Kabi AG
13.3 GlaxoSmithKline Plc.
13.4 Hebei Changshan Biochemical Pharmaceutical Co. Ltd.
13.5 Hikma Pharmaceuticals PLC
13.6 Mylan N.V.
13.7 Novartis AG
13.8 Pfizer Inc
13.9 Teva Pharmaceutical Industries Ltd.
13.10 Bayer AG
13.11 Bristol Myers Squibb Company
List of Tables
1 Global Diabetic Nephropathy Market Outlook, By Region (2021-2030) ($MN)
2 Global Diabetic Nephropathy Market Outlook, By Type (2021-2030) ($MN)
3 Global Diabetic Nephropathy Market Outlook, By Type-1 Diabetes (2021-2030) ($MN)
4 Global Diabetic Nephropathy Market Outlook, By Type-2 Diabetes (2021-2030) ($MN)
5 Global Diabetic Nephropathy Market Outlook, By Other Types (2021-2030) ($MN)
6 Global Diabetic Nephropathy Market Outlook, By Diagnosis Type (2021-2030) ($MN)
7 Global Diabetic Nephropathy Market Outlook, By Blood Test (2021-2030) ($MN)
8 Global Diabetic Nephropathy Market Outlook, By Urine Test (2021-2030) ($MN)
9 Global Diabetic Nephropathy Market Outlook, By Imaging Test (2021-2030) ($MN)
10 Global Diabetic Nephropathy Market Outlook, By Renal Function Testing (2021-2030) ($MN)
11 Global Diabetic Nephropathy Market Outlook, By Kidney Biopsy (2021-2030) ($MN)
12 Global Diabetic Nephropathy Market Outlook, By Other Diagnosis Types (2021-2030) ($MN)
13 Global Diabetic Nephropathy Market Outlook, By Treatment (2021-2030) ($MN)
14 Global Diabetic Nephropathy Market Outlook, By Medication (2021-2030) ($MN)
15 Global Diabetic Nephropathy Market Outlook, By Diuretics (2021-2030) ($MN)
16 Global Diabetic Nephropathy Market Outlook, By Antioxidant Inflammation Modulator (2021-2030) ($MN)
17 Global Diabetic Nephropathy Market Outlook, By Angiotensin Receptor Blockers (2021-2030) ($MN)
18 Global Diabetic Nephropathy Market Outlook, By Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors) (2021-2030) ($MN)
19 Global Diabetic Nephropathy Market Outlook, By Renin Inhibitors (2021-2030) ($MN)
20 Global Diabetic Nephropathy Market Outlook, By Calcium Channel Blockers (2021-2030) ($MN)
21 Global Diabetic Nephropathy Market Outlook, By Other Medications (2021-2030) ($MN)
22 Global Diabetic Nephropathy Market Outlook, By Kidney Dialysis (2021-2030) ($MN)
23 Global Diabetic Nephropathy Market Outlook, By Transplant (2021-2030) ($MN)
24 Global Diabetic Nephropathy Market Outlook, By Route of Administration (2021-2030) ($MN)
25 Global Diabetic Nephropathy Market Outlook, By Oral (2021-2030) ($MN)
26 Global Diabetic Nephropathy Market Outlook, By Parental (2021-2030) ($MN)
27 Global Diabetic Nephropathy Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
28 Global Diabetic Nephropathy Market Outlook, By Distribution Channel (2021-2030) ($MN)
29 Global Diabetic Nephropathy Market Outlook, By Online Pharmacy (2021-2030) ($MN)
30 Global Diabetic Nephropathy Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
31 Global Diabetic Nephropathy Market Outlook, By End User (2021-2030) ($MN)
32 Global Diabetic Nephropathy Market Outlook, By Hospitals (2021-2030) ($MN)
33 Global Diabetic Nephropathy Market Outlook, By Homecare (2021-2030) ($MN)
34 Global Diabetic Nephropathy Market Outlook, By Specialty Centers (2021-2030) ($MN)
35 Global Diabetic Nephropathy Market Outlook, By Other End Users (2021-2030) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
